https://orcid.org/0000-0003-3397-0946
References
- Campa M, Mansouri B, Warren R, et al. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis [published correction appears in Dermatol Ther (Heidelb). 2016;6(2):305]. Dermatol Ther (Heidelb). 2016;6(1):1–12.
- Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529–534.
- Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
- D’Adamio SD, Silvaggio D, Lombardo P, et al. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. Expert Opin Drug Saf. 2019;18(11):1031–1041.
- van de Kerkhof PC, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Eur Acad Dermatol Venereol. 2015;29(10):2002–2010.
- Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871–81.e1-30.
- Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185.
- Kaushik SB, Lebwohl MG. Review of safety and efficacy of approved systemic psoriasis therapies. Int J Dermatol. 2019;58:649–658.
- Green LJ, Yamauchi PS, Kircik LH. Comparison of the safety and efficacy of tumor necrosis factor inhibitors and interleukin-17 inhibitors in patients with psoriasis. J Drugs Dermatol. 2019;18(8):776–788.
- Campanati A, Ganzetti G, Giuliodori K, et al. Biologic therapy in psoriasis: safety profile. Curr Drug Saf. 2016;11(1):4–11.
- Mansouri Y, Goldenberg G. Biologic safety in psoriasis: review of long-term safety data. J Clin Aesthet Dermatol. 2015;8(2):30–42.
- Menter A, Strober B, Kaplan D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
- Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45:279–286.
- Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2019;19(1):45–54.
- Loft N, Vaengebjerg S, Halling-Sønderby A-S, et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2019. doi: 10.1111/jdv.16073. Epub ahead of print.
- Smith MK, Pai J, Panaccione R, et al. Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 2019;19(1):162.
- Li W, Ghamrawi R, Haidari W, et al. Risankizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother. 2019. doi: 10.1177/1060028019885836. Epub ahead of print.